When pharmacological treatment is needed to reach control of gestational diabetes mellitus (GDM), insulin is still first-line agent but metformin has been progressively pointed as an effective alternative. Our aim is to confirm whether metformin is an effective and safe option to insulin, by comparing maternal and foetal outcomes between women with GDM treated with these drugs. Retrospective study including 399 women with GDM, 135 needing pharmacological treatment. Comparison of demographic features, risk factors for GDM, maternal and foetal outcomes between women treated with insulin (G1, 41/135) and those treated with metformin (G2, 94/135). X 2 /Fisher tests were performed. Significance was set at p < 0.05. Both groups showed similar features and risk factors for GDM, except for chronic hypertension, more prevalent in G1. Therapy with insulin showed poorer metabolic control with higher rate of pregnant with HbA1c ≥ 6% (42 mmol/mol) (25.6 vs 4.5%, p = 0.001) and more polihydramnios (14.6% vs 3.2%, p = 0.023). A higher rate of caesarean was observed in G1, however, with no statistical difference (42.5% vs 26.9%, p = 0.076). There were more newborns weighing < 2500 g in women treated with metformin. No other outcome showed difference with statistical significance, namely maternal weight gain, macrosomia or neonatal comorbidities. Metformin allowed a good metabolic control with maternal and foetal outcomes similar to insulin. Metformin has proven effective as a pharmacological option to insulin. Prospective and randomized studies are needed as well as evaluation of long term benefits of metformin.
Introduction
A tendency to the rise of gestational diabetes mellitus (GDM) has been observed [1] . This rise is in relation to an increase in predisposing maternal characteristics [2] and implies more women in risk of maternal and foetal complicationsspontaneous abortion, foetal anomalies, pre-eclampsia, foetal demise, macrosomia, neonatal hypoglycaemia, neonatal hyperbilirubinaemia, among others [1] ; those should be considered and screened during prenatal surveillance. Long-term complications in offspring of pregnant women with diabetes should also be mentioned, with increased risk of overweight, obesity and type 2 diabetes [1, 3] .
Management of GDM aims to achieve glycaemic targets and, many times, lifestyle changes are sufficient [4] . These changes include exercise and dietary recommendations, the last ones concerning number and frequency of meals as well as its quality. Despite lack of internationally recognized guidelines on GDM-oriented diet, its aim is to provide adequate energy to promote maternal and foetal health while helping to achieve glycaemic goals [2] and it focuses on some degree of carbohydrate restriction. When this is not enough, pharmacological treatment is initiated.
A study comparing untreated pregnant women diagnosed with GDM with either treated or nondiabetics showed a higher composite adverse outcome without medication, with more metabolic complications and large for gestational age (GA) . No difference between nondiabetic and treated pregnant women was found in the same study [5] .
Decrease in relative risk of birthweight > 4 kg and large for gestational age (GA) neonates has been showed in other studies [6, 7] . Pharmacologic treatment is also associated with fewer cases of shoulder dystocia, less hyperbilirubinaemia but higher neonatal intensive care admissions; however, evidence is inconsistent [6] [7] [8] .
Although macrosomia is reduced and metabolic control is reached, outcomes related to it such as perinatal mortality, birth trauma (brachial plexus injury and clavicular fractures) and risk of consequences in later life were not demonstrated [6] [7] [8] .
Treatment also reduces pre-eclampsia and other hypertensive disorders in pregnancy [1] .
Insulin is the classic and still first-line agent in the pharmacological treatment of GDM, recommended by American Diabetes Association [1] .
Other agents have been progressively playing a more important role. Of those agents, metformin should be emphasized, being the focus of numerous studies and representing an easier administration with a more satisfied user [9] , which is essential for compliance to treatment [10] . It is indeed considered by NICE guidelines, since 2015, a first-line agent, over insulin in most cases, specifically in all women with no contraindication to metformin and either fasting plasma glucose level inferior to 6.0 mmol/L or level inferior to 7.0 mmol/L and no complications such as macrossomia or hydramnios [11, 12] . It is also considered a reasonable and safe first-line alternative to insulin by the Society for Maternal-Fetal Medicine [10] .
Metformin has been associated with lower maternal weight gain and lower risk of hypoglycaemia [11, 13] , however, also inconsistently with increased risk of prematurity [11, 14] .
Our aim was to compare maternal and foetal outcomes among women with GDM who needed treatment with either insulin or metformin.
Methods
We present a retrospective study of all women with GDM whose pregnancy was followed in Hospital Beatriz Ângelo, Loures, Lisbon, Portugal, and who had their delivery between 2012 and 2015. Since following the pregnancy and delivering in our hospital were eligibility criteria, loss to follow-up was not an issue in the population selected.
Data was collected between 2012 and 2017. The cohort included 399 pregnant women whose GDM was diagnosed according to the results of Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) [15] study and to the criteria established by the International Association of Diabetes and Pregnancy Study Groups (IADSPG) [16] .
Pregnant women attended appointments alternately with an obstetrician or with a midwife; both dedicated to diabetes and were supervised by a dietician focused on pregnant women.
Glycaemic targets were defined as 5.3 mmol/L (95 mg/dl) fasting and preprandial and 7.8 mmol/L (140 mg/dl) 1 h after meals, according to national guidelines [9] . When glycaemic targets were not achieved with lifestyle changes, pharmacologic treatment was initiated. Deliberation on which agent to start took into consideration obstetric past, glycaemic profile and eventual complications of the current pregnancy, and patient will. Metformin was considered the preferable first agent and insulin was used in cases of known past history of GDM with difficult metabolic control, more erratic glycaemic behaviour and whenever metabolic control was not achieved despite maximum dosage of metformin [11, 12] . Reference to an endocrinologist occurred whenever insulin was started and when metformin failed to achieve metabolic control.
Pregnant women who initiated pharmacologic treatment with insulin (G1) were compared with those who initiated metformin (G2). A subgroup analyses was done to women treated exclusively with metformin, therefore excluding women treated with both drugs (G2b). There were no cases of women treated with both drugs, having started by insulin.
Demographic features, risk factors for GDM and maternal and foetal outcomes were compared.
Demographic features analysed included ethnicity, parity and body mass index (BMI) category as defined by World Health Organization.
Risk factors included previous GDM, history of macrosomia (considered as newborns weighing over 4 kg), prior spontaneous miscarriages and first-degree family history of diabetes. Chronic hypertension was also evaluated.
Maternal outcomes considered were hypertensive complications (pregnancy-induced hypertension and pre-eclampsia), weight gain (according to the American Institute of Medicine [17] ) and GA at diagnosis and at beginning of pharmacological therapy. Metabolic control, defined as glycated haemoglobin (HbA1c) in the third trimester inferior to 6% (42 mmol/mol) [1] , induction of labour and mode of delivery were also compared.
Polyhydramnios, intrauterine demise, neonatal death and ultrasound measures were also compared between groups. Ultrasound measures included percentile of estimated foetal weight (EFW) and abdominal circumference (AC). Neonatal outcomes analysed were perinatal death, prematurity, birthweight and neonatal comorbidities, including shoulder d y s t o c i a , c l a v i c l e f r a c t u r e s , h y p o g l y c a e m i a , hyperbilirubinaemia, respiratory distress syndrome, neonatal infection, congenital malformation and neonatal intensive care unit admission. χ 2 and Fisher tests were performed and significance was set at p < 0.05.
Results
Of the 399 pregnant women diagnosed with GDM, about onethird (33.8%, 135/399) did not reach metabolic control with lifestyle measures as physical activity and dietary modification.
From those who started pharmacological therapy, about one-third (G1, 30.4%, 41/135) initiated insulin analogues as first agent. The other two-thirds (G2, 69.6%, 94/135) took metformin; most of the group needed no supplementary insulin (G2b, 81.9%, 77/94) but 18% needed both agents.
There was no clear difference between groups concerning demographic features and risk factors for GDM (Table 1) . It should be noted that more than two-thirds of this population are overweight or obese. Although with no clear difference between groups, this was more prevalent in G2 (Table 1) .
Also, it is interesting to notice that, in both groups, the most frequent risk factor observed was family history of diabetes, affecting about half of each.
Rate of chronic hypertension in those treated with insulin was more than twice of that observed in women with metformin (G1 vs G2 p = 0.017, G1 vs G2b p = 0.006; Table 1 ).
Mean gestational age at time of diagnosis and subsequent beginning of pharmacologic treatment was similar ( Table 2) .
Therapy with insulin showed poorer metabolic control with higher rate of pregnant with HbA1c ≥ 6% (42 mmol/mol) (G1 vs G2 p = 0.001; G1 vs G2b p = 0.002) and more polyhydramnios; it should be noted that polyhydramnios reached statistical significance when considering the whole group treated with metformin (G2), but not when with metformin exclusively (G2b) ( Table 2) .
Higher rate of caesarean was observed in G1, however, with no statistical significance (G1 vs G2 p = 0.076, G1 vs G2b p = 0.053).
All other maternal outcomes did not differ significantly; hypertensive complications were rare and showed no statistical significance and, in both groups, most women gained reduced or adequate weight ( Table 2) .
Considering foetal outcomes (Table 3) , there were no cases of intrauterine demise (as well as no cases of neonatal deaths) reported. Small for GA, large for GA or big AC percentiles where similar between groups.
There were 4 cases of premature newborns, half whose mothers were treated with insulin and the other half treated with metformin. Those treated with insulin were born at 32 (newborn, NB 1) and 35 weeks of GA (NB 2) and weighted less than 2.5 kg. Those treated with metformin were born after spontaneous labour at 36 weeks of GA.
Regarding birthweight (Table 3) , macrosomia was similar between groups (p = 1 for both); however, newborns weighting less than 2.5 kg were more frequent in G1 with statistical significance (G1 vs G2 p = 0.007, G1 vs G2b p = 0.013). As previously mentioned, 2 of the 4 cases were premature (NB 1 and 2).
NB1 had a positive 1st trimester screening (yet normal karyotype) with a low pregnancy-associated plasma protein A (PAPP-A), added to maternal chronic hypertension and reduced maternal weight gain. Intrauterine growth restriction was diagnosed at 20 weeks of GA (EFW < p5) and progressively intensified (EFW < p3 at 32 weeks) justifying iatrogenic delivery by caesarean at this time with a birthweight of 0.930 kg. The newborn presented sexual ambiguity, with no other morphologic changes verified.
NB2 was born premature and with low birthweight (1.910 kg), belonged to a chronic hypertensive mother with low PAPP-A who initiated spontaneous labour at 35 weeks of GA.
The other two cases of low birthweight were termed newborns with weights close to the cutoff considered (2.460 kg and 2.475 kg) but still placing them in 10th percentile or below this, according to distribution curve of birth percentile by Cunha et al. [18] . In both cases, mothers gained reduced weight and, in the first, she had chronic hypertension and increased resistance of uterine arteries. Nevertheless, newborn comorbidities did not differ between groups (Table 3) .
Intensive care unit (ICU) admission happened once in the insulin group and corresponded to the previously described premature low birth newborn, NB1. Admissions to ICU in the metformin group were verified in 4 cases; reasons were 
Discussion
We highlight the absence of differences in demographic features and risk factors, which allow us to relate different outcomes with the type of pharmacological agent used. In our study, with our sample, metformin allowed to reach good metabolic control. Sub-analysis between G1 and G2b was done to exclude the bias of having in the second group women who were simultaneously benefiting from treatment with insulin.
Lower weight gain and higher risk of prematurity, related to metformin treatment in literature, were not observed. Instead, prematurity and low birthweight were more observed in the insulin group. Analysis of these cases highlights the presence of overlapping characteristics that contribute to such multifactorial disorders, thereafter not attributable to insulin treatment by itself.
With overlapping maternal and foetal outcomes when using insulin or metformin, we believe metformin has proven effective as a pharmacological option to insulin and safe considering short-term results.
We provided free, general access to standardized prenatal care and applied a uniform diagnosis which we believe are important factors for the reproducibility of this study. Nevertheless, we recognize the existant debate around GDM diagnostic criteria and the IADSPG criteria that we follow, according to our national guidelines. Each group of our study includes both women whose GDM was diagnosed in the first trimester or after 24 weeks and lack of complete agreement or even no correlation between first trimester fasting plasma glucose and results from the third trimester test has been shown [19] . Different GA of GDM diagnosis may represent different phenotypes [19] . Therefore, we acknowledge each group may be very heterogeneous inside itself and we emphasize that other institutions, applying other criteria, may have very different groups from the ones in our study.
As limitation to our study, sample size should be mentioned-a bigger sample would possibly present higher numbers of neonatal comorbidities which could have statistical significance, which was not reached in this study. Also, because of being a retrospective study, there is incomplete data, which resulted in the evaluation of variables according to the total of available results instead of the total number of cases in the group; this bias is stronger in variables concerning 3rd trimester ultrasound measures and neonatal complications, which we admit that could be underrated.
Because metformin is a more patient-friendly drug, it was more often chosen as first agent. Authors recognize that a more erratic glycaemic profile or with more intense hyperglycaemia might have increased the likelihood of considering insulin analogues as first agent. Therefore, the decision to begin with one agent or the other is a bias. This would be surpassed with a prospective and randomized controlled study.
Finally, we recognize limited value of HbA1c-it was not used to monitor treatment results nor to decide maintenance or change of treatments but it was considered as a tool to determine metabolic control for study purpose. It is use for GDM management and has been discouraged in patients without pre-existing diabetes [11] and its value may depend on anaemic status, which was not analysed in this study.
Data concerning long-term effects and benefits of metformin is needed.
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